JD.com Inc. (NASDAQ: JD) is scheduled to report second quarter 2019 earnings results on Tuesday, August 13, before market open. Analysts expect the company to report earnings of $0.07 per share on revenue of $21.7 billion.
JD.com has a strong foothold in the ecommerce market and the momentum in this area is likely to benefit the second quarter results. The company’s efforts in improving its product offerings and expanding into new markets are expected to help drive growth.
JD.com has entered into partnerships with several major retailers and these alliances are expected to be beneficial to the company. Its strong logistics network which helps in providing efficient delivery services is another advantage.
However, the economic conditions in China and the trade tensions with the US could prove to be a dampener. JD.com has been investing significantly in its business and these investments could lead to higher expenses which is another cause of concern for the quarter.
In the first quarter of 2019, JD.com reported better-than-expected revenue and earnings. Revenue grew around 21% year-over-year to RMB121.1 billion ($18 billion) while adjusted net income per ADS was RMB2.23 ($0.33).
Quarterly active customer accounts rose by 15% versus the year-ago period. Annual active customer accounts increased to 310.5 million in the twelve months ended March 31, 2019 from 305.3 million in the twelve months ended December 31, 2018.
For the second quarter of 2019, JD.com expects net revenues to grow 19-23% to a range between RMB145 billion and RMB150 billion.
JD.com’s shares have gained 26% so far this year. The majority of analysts have rated the stock as Buy and it has a 12-month price target of $35.10.
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications